Sarilumab medical insurance price

Sarilumab was approved by the U.S. Food and Drug Administration (FDA) on May 22, 2017, for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs). In addition, its role in the treatment of other hyperinflammatory diseases is currently being studied, and salivolumab may be used as monotherapy (in cases of intolerance to methotrexate or where methotrexate treatment is inappropriate) or in combination with conventional DMARDs.

Salirumab is a humanized mAb (IgG1 subtype) that specifically binds mIL-6R and soluble sIL-6R, inhibiting IL6-mediated pathways involving glycoprotein 130 (gp130) and STAT-3 (a signal transducer and activator of transcription). Salirumab is a high-affinity antiIL-6 receptor antibody that may be a promising weapon in treating the dreaded hyperinflammatory phase by improving outcomes for patients with rheumatoid arthritis. In addition to neutropenia and the relative risk of bacterial infection, other possible adverse effects of salirumab may manifest as increased transaminase levels (without clinically apparent liver injury), increased total cholesterol levels (especially low-density lipoprotein levels), and injection site reactions (erythema or pruritus).

The patent drug of Salirutumab is a new type of drug for treating diseases. It has not yet been launched in China, so it is not covered by medical insurance. Patients cannot yet purchase this drug in domestic hospitals or pharmacies. The common dosage form of Salirutumab's original drug is injection, which has been marketed overseas. The price of the European version of the specification200mg*2 per box is around 17,500 (the price may fluctuate due to the exchange rate). There are currently no generic Salirutumab produced in other countries.